Metabolic · Placeholder catalog data
GLP-2 (T)
A synthetic 39-amino-acid peptide engineered as a unimolecular dual agonist at the GIP and GLP-1 receptors. Extensive recent literature in glycemic and weight research.
130 credits
Paid from your credit pool at checkout. Bulk quantities discount automatically.
Available variants
Pricing and fulfillment information is placeholder data.
| Amount | SKU | Credits | MSRP | Availability | Margin estimate |
|---|---|---|---|---|---|
| 5 mg | PTS-TIR-5 | 26 credits | $79 | Ready | 67% estimate |
| 10 mg | PTS-TIR-10 | 32 credits | $139 | Ready | 77% estimate |
| 20 mg | PTS-TIR-20 | 38 credits | $249 | Ready | 85% estimate |
| 30 mg | PTS-TIR-30 | 45 credits | $329 | 10 business days | 86% estimate |
Margin estimate treats 1 credit as $1 and compares estimated wholesale credit cost with placeholder MSRP. It excludes shipping, taxes, and other costs.
Buy more, save more
Quantity breaks apply per line item and are deducted automatically at checkout.
| Quantity per line | Discount | Example (5 mg unit) |
|---|---|---|
| 10+ units | 5% off | 10 × 26 credits → 247 credits |
| 25+ units | 10% off | 25 × 26 credits → 585 credits |
| 50+ units | 15% off | 50 × 26 credits → 1,105 credits |
| 100+ units | 20% off | 100 × 26 credits → 2,080 credits |
Specifications
- CAS
- 2023788-19-2
- Formula
- C225H348F2N48O68
- Molecular weight
- 4813.53 g/mol
- Sequence
- YXEGTFTSDYSIYLDKQAAXEFVQWLIAGGPSSGAPPPS (Aib at positions 2, 13; C20 diacid)
- Purity
- ≥99%
- Appearance
- White lyophilized powder
- Storage
- Store lyophilized at 2–8 °C, protected from light and moisture
Quality record
COA status
COA listedLot PTS-TIR-2607
Placeholder reference. Verify the active lot before ordering.
Research background
Tirzepatide is a 39-amino-acid synthetic peptide designed as a balanced agonist at the GIP and GLP-1 receptors, modified with α-aminoisobutyric acid residues and a C20 fatty diacid moiety to confer metabolic stability and albumin binding.
Clinical and preclinical literature across the SURPASS and SURMOUNT program has reported effects on glycemic control, body weight, hepatic steatosis, and lipid profiles. The molecule is approved as Mounjaro® and Zepbound®.
Supplied as a research-grade reference for investigation of dual incretin receptor pharmacology. Not supplied for human use.
Mechanism: Literature describes Tirzepatide as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, engaging both incretin pathways.
Research use only
For research use only. Not for human or veterinary use.